Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Pharmaceuticals Corp.

Division of Novartis AG

Latest From Sandoz Pharmaceuticals Corp.

Market Intel: Pain Is Biggest Market For Transdermal Drug Delivery But Not A Patch Over Neuro For Growth

The growing aging population and rising obesity rates are paving the way for patch-based drug delivery systems to treat such common age-related diseases as Alzheimer's and Parkinson's, hormonal deficiencies, heart disease, as well as for managing acute and chronic pain patients. According to a new report by Meddevicetracker, the global market for transdermal patch products will reach $8.1bn by 2021, a CAGR of 2.9% from 2016. In this feature, we'll take a closer look at the overall market and the key players in the individual segments in this overall market. We'll take a deep dive into the neurological disorders segment, which is expected to see the biggest growth in the overall segment. We'll also feature physician specialty surveys outlining the pros and cons of using patch-based systems.

Combination Products Market Intelligence

Steady M&A Flow Lifts Fosun

Continuing with its dual strategy driven by innovation and internationalization, Fosun Pharmaceutical recently announced two acquisitions on the trot. The deals separately tap into growth opportunities in new biologic products and build on Fosun’s presence in Africa.

BioPharmaceutical China

Deal-Making Firm On Fosun’s Agenda As Overseas Revenues Spurt

With overseas revenues rising sharply in the first half of 2017, Fosun Pharma expects to build on its global investment strategy at a fast pace, striking more deals to acquire products and companies from developed markets.

BioPharmaceutical China

A Look At Payers' Early Game Plans For Driving Biosimilar Use

Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.

Biosimilars Market Access
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • Edgar Fullagar, Acting Pres. & CEO
    Urs Naegelin, CFO
    Michael J DuBois, VP, Bus. Dev. & Licensing
    Rick Lane, SVP, Mktg
    Dan Hauser, Pres., Sandoz Res. Institute
  • Contact Info
  • Sandoz Pharmaceuticals Corp.
    Phone: (201) 503-7500
    59 Route 10
    East Hanover, NJ 07936
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register